NCT06438627 2024-07-16
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
11 trialsNCT05854849 2023-05-11
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Sun Yat-sen University
Phase 3 Recruiting
NCT04586088 2023-05-06
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
Sun Yat-sen University
Phase 2 Unknown
NCT05549466 2023-02-08
Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC
Sun Yat-sen University
Phase 2 Unknown
NCT04350190 2023-01-13
Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Guilin Medical University, China
Phase 2 Completed
NCT02874651 2022-01-11
ADVANCE
Sun Yat-sen University
Phase 2 Terminated
NCT04547088 2020-09-14
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04548271 2020-09-14
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT03612219 2018-08-02
Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma
Guilin Medical University, China
Phase 2 Unknown
NCT03130270 2018-05-16
Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma
Guilin Medical University, China
Phase 2 Unknown
NCT03213587 2017-07-11
Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Zhejiang Cancer Hospital
Phase 2 Unknown